VIDEO: Surgeon summarizes award-winning abstract presentation on DR treatment

Aug 29, 2023

WIO 2023: ZETA-1 phase 2 trial safety and tolerability results for APX3330

Aug 26, 2023

ASRS 2023: ZETA-1 phase 2 trial efficacy results for APX3330 with David Lally, MD

Aug 9, 2023

VIDEO: Ocuphire to discuss APX3330 outcome measure with FDA

Aug 8, 2023

David Lally, MD: Efficacy of Oral APX3330 for Diabetic Retinopathy

Aug 6, 2023

ON THE HORIZON: DIABETIC RETINOPATHY TREATMENTS — WITHOUT INJECTIONS

Jul 1, 2023

Phase 2 ZETA-1 Trial Suggests Promise of APX3330 in Diabetic Retinopathy

Jun 27, 2023

Shrinking Night Vision Disturbances

Jun 1, 2023

Phentolamine (Nyxol) Clinical Trials Next in the Pipeline for Presbyopia

Apr 27, 2023

Potential Wide Use for Ocuphire’s APX-3330: An Oral Drug to Prevent Diabetic Retinopathy Progression—Results of the Phase 2 ZETA-1 Trial

Mar 23, 2023

• 1
• 2
• 3
• 4
• 5
• Next »